<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(4)</volume><submitter>Reikvam H</submitter><pubmed_abstract>Endocan is a soluble dermatan sulfate proteoglycan expressed by endothelial cells and detected in serum/plasma. Its expression is increased in tumors/tumor vessels in several human malignancies, and high expression (high serum/plasma levels or tumor levels) has an adverse prognostic impact in several malignancies. The p14 endocan degradation product can also be detected in serum/plasma, but previous clinical studies as well as previously unpublished results presented in this review suggest that endocan and p14 endocan fragment levels reflect different biological characteristics, and the endocan levels seem to reflect the disease heterogeneity in acute leukemia better than the p14 fragment levels. Furthermore, decreased systemic endocan levels in previously immunocompetent sepsis patients a</pubmed_abstract><journal>Biomolecules</journal><pagination>492</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9027427</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.</pubmed_title><pmcid>PMC9027427</pmcid><pubmed_authors>Lassalle P</pubmed_authors><pubmed_authors>Reikvam H</pubmed_authors><pubmed_authors>Hatfield KJ</pubmed_authors><pubmed_authors>Wendelbo O</pubmed_authors><pubmed_authors>Lindas R</pubmed_authors><pubmed_authors>Bruserud O</pubmed_authors></additional><is_claimable>false</is_claimable><name>Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.</name><description>Endocan is a soluble dermatan sulfate proteoglycan expressed by endothelial cells and detected in serum/plasma. Its expression is increased in tumors/tumor vessels in several human malignancies, and high expression (high serum/plasma levels or tumor levels) has an adverse prognostic impact in several malignancies. The p14 endocan degradation product can also be detected in serum/plasma, but previous clinical studies as well as previously unpublished results presented in this review suggest that endocan and p14 endocan fragment levels reflect different biological characteristics, and the endocan levels seem to reflect the disease heterogeneity in acute leukemia better than the p14 fragment levels. Furthermore, decreased systemic endocan levels in previously immunocompetent sepsis patients a</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-05-18T12:07:45.623Z</modification><creation>2025-02-19T03:58:23.332Z</creation></dates><accession>S-EPMC9027427</accession><cross_references><pubmed>35454082</pubmed><doi>10.3390/biom12040492</doi></cross_references></HashMap>